MK-677 vs Sermorelin

Both are classed here as growth hormone secretagogues, so this is a within-class choice: the mechanism is broadly shared and what separates them is kinetics, route, and how much has actually been tested.

The overlap is recovery and sleep and muscle growth. On this site's goal weighting — an editorial priority score, not a measure of effect size — MK-677 rates 5/5 for recovery and sleep and Sermorelin rates 4/5. Outside that overlap only MK-677 goes further, carrying weight for appetite control; Sermorelin's declared goals stop at the overlap.

Sermorelin sits one step firmer: approval from a regulator somewhere, though not a current FDA or EMA label — it was FDA approved as Geref, then withdrawn for commercial reasons. MK-677 has controlled human trials behind it, without an approval — never approved, and trials flagged higher fasting glucose. One tier is a real difference but not a decisive one; it should not on its own settle the choice.

MK-677 is taken by mouth; Sermorelin is a subcutaneous injection. That is the difference most people actually feel: Sermorelin means reconstituting a vial and injecting; MK-677 does not require either. If needles are the deciding factor, this line settles it before any of the rest matters.

The kinetics are more than two orders of magnitude apart — 24 h for MK-677 against 12 min for Sermorelin — and yet both are dosed once daily. That schedule is convention rather than clearance, which is worth knowing before you assume the two behave the same way between doses.

Committed time differs: MK-677 runs 16 weeks, Sermorelin runs 12 weeks.

Sermorelin is rated beginner here and MK-677 intermediate. That rating is about how much can go wrong in handling, dosing and monitoring, not about how well either works.